Final consortium meeting in Innsbruck, AT
MITIGATE held its final consortium meeting at the Medical University in Innsbruck, Austria on September 12-13. The project will conclude at the end of September 2017.
Consortium members presented their results and achievements of the MITIGATE project over the past four years, and discussed opportunities on how to continue the fruitful collaboration after the funding period ends.
The MITIGATE clinical study shows promising results, and partners Advanced Accelerator Applications and the Medical University Innsbruck look to continue their collaboration in the development of nuclear medicine tracers for the diagnosis, and eventually treatment, of GIST.
MITIGATE has been highly successful in achieving the goals it set out at the beginning of the project and there are clear strategies for the future exploitation and marketing of MITIGATE results.
MITIGATE newsletter – 4th edition
In its 4th newsletter, the MITIGATE consortium presents the studies conducted work packages 7 and 8: The efforts of WP7 concentrated on the development of a protocol for minimally invasive treatment and studies on robotic assistance. Within WP8, the assessment of new MR imaging methods of GIST tumour models into clinical practice has been investigated. More details on the on-going MITIGATE clinical study are also included.
You can read the newsletter here.
Final consortium meeting in Innsbruck/AT
MITIGATE partners will meet for the fifth and final general assembly on September 13th, 2017 at the Medical University of Innsbruck, Austria.
At the meeting, the final results of the project will be shared and discussed among all collaborating scientists. The consortium will focus on how these results can and will be exploited after the project concludes, in order to bring the project’s developments from the bench to the bedside and into clinical routine.
MITIGATE shares latest results at RöKo 2017
MITIGATE was recently present at the German Röntgen Congress 2017 in Leipzig, Germany. The latest results and information were shared at a dedicated project booth during the congress exhibition. Furthermore, MITIGATE organised a workshop where the project’s innovations which are ready for, or close to, the market were introduced. Project results were also introduced and discussed by MITIGATE partners during a Highlight Session on GIST.
The German Röntgen Congress is the annual congress of the German Society of Radiology and attrachts approximately 7,000 visitors each year.
Innovation Workshop at German Röntgen Conress
MITIGATE will host its Innovation Workshop at the German Röntgen Congress 2017 on May 26th from 10:00-12:00. Here, the consortium will present innovations for diagnostic imaging and minimally invasive treatment which are ready for the market.
Additionally, MITIGATE will also have an exhibition booth with additional information about the project and its results and achievements.
The programme of the Innovation Workshop can be seen below:
Start of patient recruitment for MITIGATE clinical study
MITIGATE is recruiting patients with metastatic GIST who are experiencing tumour progression while under treatment with Imatinib (Glivec®, Gleevec™) for a diagnostic clinical study.
MITIGATE uses an innovative imaging approach focusing on progressive tumour lesions. While the approach is diagnostic rather than therapeutic, patients may derive real benefits from the new imaging procedure, such as improved tumour volume definition and better detection of disease.
European patients with metastatic GIST can fill out the enrolment questionnaire to determine whether you meet the requirements for participation in our study. You access the questionnaire by clicking here.
MITIGATE newsletter – 3rd edition
In the third newsletter, MITIGATE presents achievements & upcoming activities regarding the first-in-human application of the diagnostic tracer developed during the project.
MITIGATE newsletter – 3rd edition
3rd IRDiRC Conference, February 8-9 in Paris, France
Save the date for the third International Rare Diseases Research Consortium conference in Paris, France
The third conference of the International Rare Diseases Research Consortium (IRDiRC) will take place February 8-9, 2017 in Paris, France at the conference center of Université Pierre et Marie Curie Jussieu.
Since it’s launch in 2011, IRDiRC has made considerable advances in rare diseases research. This conference presents a unique opportunity to reflect upon the progress made, confront barriers, and form new collaborations to take on challenges posed by rare diseases.
All stakeholders – active investigators, policy makers, young researchers and patient advocates alike – active in the area of rare diseases from across the globe are invited to join the IRDiRC conference to celebrate achievements in the field, identify future milestones and goals, and work toward bringing diagnoses and therapies to all rare disease patients.
More information on the IRDiRC is available on the website: www.irdirc.org
Last chance to participate in the End-User survey
You are still able to help us assess the community’s interest in MITIGATE’s innovative results!
In order to successfully exploit the project’s developments, and support us in bringing products to the European patients, we kindly ask you to participate in the MITIGATE End-User survey.
You can access the survey here
MITIGATE session at ECR 2016
The MITIGATE consortium organised a session on clinical trials in interventional radiology on the occasion of the European Congress of Radiology 2016 in Vienna. The session “MITIGATE what does it take to perform clinical trials in interventional radiology?” attracted a significant number of attendees, and discussion on setting up and running trials in interventional radiology.
Speakers and moderators, Prof. Dr. Werner Jaschke and Prof. Dr. Stefan Schönberg, were pleased to see a high interest among radiologists in the presented topics.
Click here to get more information about the session and to watch it online*
*Please note that users must register online in order to watch sessions from the ECR